#United States #Veeva Systems #Rare Diseases #BioMarin Pharmaceutical #Pleasanton, San Rafael

Strengthening the Future of Rare Disease Therapies

In a significant move within the biotechnology industry, Veeva Systems (NYSE: VEEV) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) have announced a strategic partnership that promises to transform the way innovative therapies for rare diseases are developed and brought to market. This long-term enterprise agreement builds on their established relationship, emphasizing collaboration to enhance operational efficiency, speed, and agility.

Accelerating Innovation and Efficiency

The expanded partnership aims to create a more streamlined approach to the development and commercialization of therapies specifically designed for genetically defined conditions. Alexander Hardy, President and CEO of BioMarin, expressed optimism about this collaboration, stating, "This strategic partnership marks an important next step in our digital evolution. By combining our scientific expertise with Veeva's technological prowess, we believe we can more rapidly deliver our transformative medicines to patients in need."

Veeva Systems, known for its cloud-based solutions tailored for the life sciences sector, will provide comprehensive support in software, data, services, and consulting. This alignment is expected to optimize both the healthcare professional's and the patient's experience, establishing more effective channels for communication and data analysis.

A Legacy of Excellence

Both companies share a commitment to innovation and excellence, seeking to redefine the landscape of rare disease treatment. Veeva CEO Peter Gassner reiterated the mutual goal of product excellence and customer success, stating, "Our partnership has always been rooted in shared values. I look forward to continuing our support for BioMarin as they advance their new medicines and reach more patients worldwide."

With a history dating back to 1997, BioMarin has made its mark in the pharmaceutical industry with a robust portfolio of eight commercial therapies and a strong pipeline of clinical and preclinical projects. The company’s distinctive approach to drug discovery focuses on maximizing the potential of genetic science to develop pioneering therapies that significantly impact patients’ lives.

Commitment to Patients and Stakeholders

The partnership's ultimate goal is to harness the strengths and capabilities of both companies to improve the time it takes to reach life-changing treatments for patients affected by rare diseases. BioMarin has made a name for itself as a leader in biotechnology, particularly concerning genetic disorders, and relies on innovative research and product development strategies that meet the unique needs of this patient population.

As a Public Benefit Corporation, Veeva Systems is dedicated to balancing the interests of all stakeholders, including their customers, employees, and the broader healthcare industry. Their commitment to innovation and customer success will play a crucial role in empowering BioMarin to pursue its mission of enhancing patient lives through advanced biopharmaceutical solutions.

Looking Forward

This strategic partnership between Veeva and BioMarin signifies a promising chapter in the pursuit of effective treatments for rare diseases, with the expectation that their combined efforts will yield significant advancements in patient care and treatment options. As both companies prepare to leverage this alliance, the global healthcare community observes with anticipation the potential benefits and innovations that will arise from this collaboration.

In conclusion, as Veeva Systems and BioMarin Pharmaceutical embark on this journey together, they set a precedent for how biotechnology firms can harness technology to improve operational efficiency, speed up therapy development, and ultimately deliver hope to patients in need of life-saving treatments.